ARTICLE | Company News
Galapagos, J&J terminate inflammation deal
March 18, 2015 1:49 AM UTC
Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) and the Janssen Pharmaceutica NV unit of Johnson & Johnson (NYSE:JNJ) terminated a 2007 deal to develop small molecules for inflammation.
Galapagos will regain all rights to GLPG1690, a selective autotaxin inhibitor. It plans to start a Phase II trial of the compound in early 2016 to treat idiopathic pulmonary fibrosis (IPF). Galapagos spokesperson Elizabeth Goodwin said the company will consider partnering GLPG1690 after the trial. ...